

CONTENTS

VOLUME I

<i>Tables of Cases</i>	xxv
<i>Tables of Legislation</i>	ci
<i>List of Abbreviations</i>	clv
<i>List of Contributors</i>	clxiii
<i>Note on UK Legislation</i>	clxv

A INTRODUCTION AND OVERVIEW

Introduction	3
--------------	---

B FUNDAMENTALS

1. Overview	17
2. International Treaties	21
3. Skilled Addressee	27
Australia	3.1.01
Canada	3.2.01
China	3.3.01
India	3.4.01
Japan	3.5.01
United States	3.6.01
Europe Overview	3.7.01
France	3.8.01
Germany	3.9.01
Italy	3.10.01
Netherlands	3.11.01
United Kingdom	3.12.01
4. Interpretation (Construction) of Patent Claims and Specifications	55
Australia	4.1.01
Canada	4.2.01
China	4.3.01
India	4.4.01
Japan	4.5.01
United States	4.6.01
Europe Overview	4.7.01
France	4.8.01
Germany	4.9.01

CONTENTS

VOLUME II

I DEFENCES TO INFRINGEMENT

49. Overview	3
50. Prior Secret Use	5
Australia	50.1.01
Canada	50.2.01
China	50.3.01
India	50.4.01
Japan	50.5.01
United States	50.6.01
Europe Overview	50.7.01
France	50.8.01
Germany	50.9.01
Italy	50.10.01
Netherlands	50.11.01
United Kingdom	50.12.01
51. Experimental Use and Clinical Trials	25
Australia	51.1.01
Canada	51.2.01
China	51.3.01
India	51.4.01
Japan	51.5.01
United States	51.6.01
Europe Overview	51.7.01
France	51.8.01
Germany	51.9.01
Italy	51.10.01
Netherlands	51.11.01
United Kingdom	51.12.01
52. Acts Done to Obtain Regulatory Approval (The Bolar Exemption)	45
Australia	52.1.01
Canada	52.2.01
China	52.3.01
India	52.4.01

Japan	52.5.01
United States	52.6.01
Europe Overview	52.7.01
France	52.8.01
Germany	52.9.01
Italy	52.10.01
Netherlands	52.11.01
United Kingdom	52.12.01
53. Non-Infringement Declarations and Strategy	61
Australia	53.1.01
Canada	53.2.01
China	53.3.01
India	53.4.01
Japan	53.5.01
United States	53.6.01
Europe Overview	53.7.01
France	53.8.01
Germany	53.9.01
Italy	53.10.01
Netherlands	53.11.01
United Kingdom	53.12.01
54. Exhaustion of Rights and Parallel Importing	83
Australia	54.1.01
Canada	54.2.01
China	54.3.01
India	54.4.01
Japan	54.5.01
United States	54.6.01
Europe Overview	54.7.01
France	54.8.01
Germany	54.9.01
Italy	54.10.01
Netherlands	54.11.01
United Kingdom	54.12.01
 J PATENT LITIGATION STRATEGIES 	
55. Overview	109
56. Court Hierarchies and Appeal Routes	115
Australia	56.1.01
Canada	56.2.01
China	56.3.01
India	56.4.01

Japan	56.5.01
United States	56.6.01
Europe Overview	56.7.01
France	56.8.01
Germany	56.9.01
Italy	56.10.01
Netherlands	56.11.01
United Kingdom	56.12.01
 57. Overview of Litigation	 139
Australia	57.1.01
Canada	57.2.01
China	57.3.01
India	57.4.01
Japan	57.5.01
United States	57.6.01
Europe Overview	57.7.01
France	57.8.01
Germany	57.9.01
Italy	57.10.01
Netherlands	57.11.01
United Kingdom	57.12.01
 58. Preliminary Injunctions	 179
Australia	58.1.01
Canada	58.2.01
China	58.3.01
India	58.4.01
Japan	58.5.01
United States	58.6.01
Europe Overview	58.7.01
France	58.8.01
Germany	58.9.01
Italy	58.10.01
Netherlands	58.11.01
United Kingdom	58.12.01
 59. Split Trials	 203
Australia	59.1.01
Canada	59.2.01
China	59.3.01
India	59.4.01
Japan	59.5.01
United States	59.6.01
Europe Overview	59.7.01
France	59.8.01

Germany	59.9.01
Italy	59.10.01
Netherlands	59.11.01
United Kingdom	59.12.01
60. Summary Judgments/Declaratory Judgments	219
Australia	60.1.01
Canada	60.2.01
China	60.3.01
India	60.4.01
Japan	60.5.01
United States	60.6.01
Europe Overview	60.7.01
France	60.8.01
Germany	60.9.01
Italy	60.10.01
Netherlands	60.11.01
United Kingdom	60.12.01
61. Multi-Jurisdiction Strategy	239
Australia	61.1.01
Canada	61.2.01
China	61.3.01
India	61.4.01
Japan	61.5.01
United States	61.6.01
Europe Overview	61.7.01
France	61.8.01
Germany	61.9.01
Italy	61.10.01
Netherlands	61.11.01
United Kingdom	61.12.01
62. Practicalities of Litigation	263
Australia	62.1.01
Canada	62.2.01
China	62.3.01
India	62.4.01
Japan	62.5.01
United States	62.6.01
Europe Overview	62.7.01
France	62.8.01
Germany	62.9.01
Italy	62.10.01
Netherlands	62.11.01
United Kingdom	62.12.01

63. Settlement of Litigation	287
Australia	63.1.01
Canada	63.2.01
China	63.3.01
India	63.4.01
Japan	63.5.01
United States	63.6.01
Europe Overview	63.7.01
France	63.8.01
Germany	63.9.01
Italy	63.10.01
Netherlands	63.11.01
United Kingdom	63.12.01

K. REGULATORY APPROVAL

64. Overview	303
65. Regulatory Bodies and Relevant Legislation	305
Australia	65.1.01
Canada	65.2.01
China	65.3.01
India	65.4.01
Japan	65.5.01
United States	65.6.01
Europe Overview	65.7.01
France	65.8.01
Germany	65.9.01
Italy	65.10.01
Netherlands	65.11.01
United Kingdom	65.12.01
 66. The Pharmaceutical Regulatory Approval Process	 337
Australia	66.1.01
Canada	66.2.01
China	66.3.01
India	66.4.01
Japan	66.5.01
United States	66.6.01
Europe Overview	66.7.01
France	66.8.01
Germany	66.9.01
Italy	66.10.01
Netherlands	66.11.01
United Kingdom	66.12.01

67. The Biologicals Regulatory Approval Process	381
Australia	67.1.01
Canada	67.2.01
China	67.3.01
India	67.4.01
Japan	67.5.01
United States	67.6.01
Europe Overview	67.7.01
France	67.8.01
Germany	67.9.01
Italy	67.10.01
Netherlands	67.11.01
United Kingdom	67.12.01
68. The Medical Device Regulatory Approval Process	399
Australia	68.1.01
Canada	68.2.01
China	68.3.01
India	68.4.01
Japan	68.5.01
United States	68.6.01
Europe Overview	68.7.01
France	68.8.01
Germany	68.9.01
Italy	68.10.01
Netherlands	68.11.01
United Kingdom	68.12.01
69. The Agricultural Chemicals Regulatory Approval Process	431
Australia	69.1.01
Canada	69.2.01
China	69.3.01
India	69.4.01
Japan	69.5.01
United States	69.6.01
Europe Overview	69.7.01
France	69.8.01
Germany	69.9.01
Italy	69.10.01
Netherlands	69.11.01
United Kingdom	69.12.01
70. Regulatory Filing Strategies Adopted by Innovator Companies	465
Australia	70.1.01
Canada	70.2.01

China	70.3.01
India	70.4.01
Japan	70.5.01
United States	70.6.01
Europe Overview	70.7.01
France	70.8.01
Germany	70.9.01
Italy	70.10.01
Netherlands	70.11.01
United Kingdom	70.12.01
71. Regulatory Filing Strategies Adopted by Generic Companies	479
Australia	71.1.01
Canada	71.2.01
China	71.3.01
India	71.4.01
Japan	71.5.01
United States	71.6.01
Europe Overview	71.7.01
France	71.8.01
Germany	71.9.01
Italy	71.10.01
Netherlands	71.11.01
United Kingdom	71.12.01
72. Other Relevant Regulatory Laws	493
Australia	72.1.01
Canada	72.2.01
China	72.3.01
India	72.4.01
Japan	72.5.01
United States	72.6.01
Europe Overview	72.7.01
France	72.8.01
Germany	72.9.01
Italy	72.10.01
Netherlands	72.11.01
United Kingdom	72.12.01
L DATA EXCLUSIVITY	
73. Overview	529
74. Comparison of Data Exclusivity with Other Rights	533
Australia	74.1.01
Canada	74.2.01
China	74.3.01

India	74.4.01
Japan	74.5.01
United States	74.6.01
Europe Overview	74.7.01
France	74.8.01
Germany	74.9.01
Italy	74.10.01
Netherlands	74.11.01
United Kingdom	74.12.01
 75. New Chemical Entity Data Exclusivity Periods for Pharmaceuticals	 553
Australia	75.1.01
Canada	75.2.01
China	75.3.01
India	75.4.01
Japan	75.5.01
United States	75.6.01
Europe Overview	75.7.01
France	75.8.01
Germany	75.9.01
Italy	75.10.01
Netherlands	75.11.01
United Kingdom	75.12.01
 76. Other Data Exclusivity Periods for Pharmaceuticals	 565
Australia	76.1.01
Canada	76.2.01
China	76.3.01
India	76.4.01
Japan	76.5.01
United States	76.6.01
Europe Overview	76.7.01
France	76.8.01
Germany	76.9.01
Italy	76.10.01
Netherlands	76.11.01
United Kingdom	76.12.01
 77. Certified (Listed) Patents and Approval of Generic Drugs	 583
Australia	77.1.01
Canada	77.2.01
China	77.3.01
India	77.4.01
Japan	77.5.01
United States	77.6.01
Europe Overview	77.7.01

France	77.8.01
Germany	77.9.01
Italy	77.10.01
Netherlands	77.11.01
United Kingdom	77.12.01
78. Data Exclusivity Strategies Adopted by Innovator Companies	601
Australia	78.1.01
Canada	78.2.01
China	78.3.01
India	78.4.01
Japan	78.5.01
United States	78.6.01
Europe Overview	78.7.01
France	78.8.01
Germany	78.9.01
Italy	78.10.01
Netherlands	78.11.01
United Kingdom	78.12.01
79. Data Exclusivity Strategies Adopted by Generic Companies	619
Australia	79.1.01
Canada	79.2.01
China	79.3.01
India	79.4.01
Japan	79.5.01
United States	79.6.01
Europe Overview	79.7.01
France	79.8.01
Germany	79.9.01
Italy	79.10.01
Netherlands	79.11.01
United Kingdom	79.12.01
80. Medical Devices, Agricultural Chemicals, and Other Non-Pharmaceuticals	641
Australia	80.1.01
Canada	80.2.01
China	80.3.01
India	80.4.01
Japan	80.5.01
United States	80.6.01
Europe Overview	80.7.01
France	80.8.01
Germany	80.9.01
Italy	80.10.01

Netherlands	80.11.01
United Kingdom	80.12.01

M COMPETITION LAW

81. Overview	651
82. Legal Basis for IP as an Exception to Competition (Antitrust) Law	655
Australia	82.1.01
Canada	82.2.01
China	82.3.01
India	82.4.01
Japan	82.5.01
United States	82.6.01
Europe Overview	82.7.01
France	82.8.01
Germany	82.9.01
Italy	82.10.01
Netherlands	82.11.01
United Kingdom	82.12.01
83. Technology Transfer Arrangements	679
Australia	83.1.01
Canada	83.2.01
China	83.3.01
India	83.4.01
Japan	83.5.01
United States	83.6.01
European Union Overview	83.7.01
France	83.8.01
Germany	83.9.01
Italy	83.10.01
Netherlands	83.11.01
United Kingdom	83.12.01
84. Tie-In Clauses/Tie-Out Clauses	701
Australia	84.1.01
Canada	84.2.01
China	84.3.01
India	84.4.01
Japan	84.5.01
United States	84.6.01
European Union Overview	84.7.01
France	84.8.01
Germany	84.9.01
Italy	84.10.01
Netherlands	84.11.01
United Kingdom	84.12.01

85. Licences which Extend beyond Patent Term	717
Australia	85.1.01
Canada	85.2.01
China	85.3.01
India	85.4.01
Japan	85.5.01
United States	85.6.01
European Union Overview	85.7.01
France	85.8.01
Germany	85.9.01
Italy	85.10.01
Netherlands	85.11.01
United Kingdom	85.12.01
86. Disclosure to Industry Standard-Setting Organizations	725
Australia	86.1.01
Canada	86.2.01
China	86.3.01
India	86.4.01
Japan	86.5.01
United States	86.6.01
Europe Overview	86.7.01
France	86.8.01
Germany	86.9.01
Italy	86.10.01
Netherlands	86.11.01
United Kingdom	86.12.01
87. Unjustified Threats of Patent Infringement Proceedings	743
Australia	87.1.01
Canada	87.2.01
China	87.3.01
India	87.4.01
Japan	87.5.01
United States	87.6.01
Europe Overview	87.7.01
France	87.8.01
Germany	87.9.01
Italy	87.10.01
Netherlands	87.11.01
United Kingdom	87.12.01
88. Competition Issues in Settlement of Litigation	759
Australia	88.1.01
Canada	88.2.01
China	88.3.01

India	88.4.01
Japan	88.5.01
United States	88.6.01
Europe Overview	88.7.01
France	88.8.01
Germany	88.9.01
Italy	88.10.01
Netherlands	88.11.01
United Kingdom	88.12.01

N OTHER IP RIGHTS

89. Overview	781
90. Confidential Information/Trade Secrets	785
Australia	90.1.01
Canada	90.2.01
China	90.3.01
India	90.4.01
Japan	90.5.01
United States	90.6.01
Europe Overview	90.7.01
France	90.8.01
Germany	90.9.01
Italy	90.10.01
Netherlands	90.11.01
United Kingdom	90.12.01
91. Plant Breeders' Rights	815
Australia	91.1.01
Canada	91.2.01
China	91.3.01
India	91.4.01
Japan	91.5.01
United States	91.6.01
Europe Overview	91.7.01
France	91.8.01
Germany	91.9.01
Italy	91.10.01
Netherlands	91.11.01
United Kingdom	91.12.01
92. Trade Marks, Passing off, and Unfair Competition	855
Australia	92.1.01
Canada	92.2.01
China	92.3.01
India	92.4.01

Japan	92.5.01
United States	92.6.01
Europe Overview	92.7.01
France	92.8.01
Germany	92.9.01
Italy	92.10.01
Netherlands	92.11.01
United Kingdom	92.12.01
O COMMERCIAL ARRANGEMENTS	
93. Overview	931
94. Research and Development Strategies	935
Australia	94.1.01
Canada	94.2.01
China	94.3.01
India	94.4.01
Japan	94.5.01
United States	94.6.01
Europe Overview	94.7.01
France	94.8.01
Germany	94.9.01
Italy	94.10.01
Netherlands	94.11.01
United Kingdom	94.12.01
95. Commercialization Strategies	963
Australia	95.1.01
Canada	95.2.01
China	95.3.01
India	95.4.01
Japan	95.5.01
United States	95.6.01
Europe Overview	95.7.01
France	95.8.01
Germany	95.9.01
Italy	95.10.01
Netherlands	95.11.01
United Kingdom	95.12.01
96. Licensing	989
Australia	96.1.01
Canada	96.2.01
China	96.3.01
India	96.4.01
Japan	96.5.01

United States	96.6.01
Europe Overview	96.7.01
France	96.8.01
Germany	96.9.01
Italy	96.10.01
Netherlands	96.11.01
United Kingdom	96.12.01
97. Assignments	1017
Australia	97.1.01
Canada	97.2.01
China	97.3.01
India	97.4.01
Japan	97.5.01
United States	97.6.01
Europe Overview	97.7.01
France	97.8.01
Germany	97.9.01
Italy	97.10.01
Netherlands	97.11.01
United Kingdom	97.12.01
98. IP Due Diligence	1033
Australia	98.1.01
Canada	98.2.01
China	98.3.01
India	98.4.01
Japan	98.5.01
United States	98.6.01
Europe Overview	98.7.01
France	98.8.01
Germany	98.9.01
Italy	98.10.01
Netherlands	98.11.01
United Kingdom	98.12.01
99. Compulsory Licences	1057
Australia	99.1.01
Canada	99.2.01
China	99.3.01
India	99.4.01
Japan	99.5.01
United States	99.6.01
Europe Overview	99.7.01
France	99.8.01
Germany	99.9.01

Italy	99.10.01
Netherlands	99.11.01
United Kingdom	99.12.01
100. Compulsory Use or Acquisition by Government	1087
Australia	100.1.01
Canada	100.2.01
China	100.3.01
India	100.4.01
Japan	100.5.01
United States	100.6.01
Europe Overview	100.7.01
France	100.8.01
Germany	100.9.01
Italy	100.10.01
Netherlands	100.11.01
United Kingdom	100.12.01
<i>Index</i>	1099

Italy	4.10.01
Netherlands	4.11.01
United Kingdom	4.12.01
5. Inventorship	109
Australia	5.1.01
Canada	5.2.01
China	5.3.01
India	5.4.01
Japan	5.5.01
United States	5.6.01
Europe Overview	5.7.01
France	5.8.01
Germany	5.9.01
Italy	5.10.01
Netherlands	5.11.01
United Kingdom	5.12.01
6. Ownership	141
Australia	6.1.01
Canada	6.2.01
China	6.3.01
India	6.4.01
Japan	6.5.01
United States	6.6.01
Europe Overview	6.7.01
France	6.8.01
Germany	6.9.01
Italy	6.10.01
Netherlands	6.11.01
United Kingdom	6.12.01
 C OBTAINING PATENT RIGHTS 	
7. Overview	177
8. Drafting Bioscience Patents	181
Australia	8.1.01
Canada	8.2.01
China	8.3.01
India	8.4.01
Japan	8.5.01
United States	8.6.01
Europe Overview	8.7.01
France	8.8.01

Germany	8.9.01
Italy	8.10.01
Netherlands	8.11.01
United Kingdom	8.12.01
9. Drafting Pharmaceutical Patents	241
Australia	9.1.01
Canada	9.2.01
China	9.3.01
India	9.4.01
Japan	9.5.01
United States	9.6.01
Europe Overview	9.7.01
France	9.8.01
Germany	9.9.01
Italy	9.10.01
Netherlands	9.11.01
United Kingdom	9.12.01
10. Overview of Procedure from Filing to Grant	283
Australia	10.1.01
Canada	10.2.01
China	10.3.01
India	10.4.01
Japan	10.5.01
United States	10.6.01
Europe Overview	10.7.01
France	10.8.01
Germany	10.9.01
Italy	10.10.01
Netherlands	10.11.01
United Kingdom	10.12.01
11. Types of Examination and When to Use Them	323
Australia	11.1.01
Canada	11.2.01
China	11.3.01
India	11.4.01
Japan	11.5.01
United States	11.6.01
Europe Overview	11.7.01
France	11.8.01
Germany	11.9.01
Italy	11.10.01

Netherlands	11.11.01
United Kingdom	11.12.01
12. Prosecution Strategies	341
Australia	12.1.01
Canada	12.2.01
China	12.3.01
India	12.4.01
Japan	12.5.01
United States	12.6.01
Europe Overview	12.7.01
France	12.8.01
Germany	12.9.01
Italy	12.10.01
Netherlands	12.11.01
United Kingdom	12.12.01
13. Types of Application and Their Uses	361
Australia	13.1.01
Canada	13.2.01
China	13.3.01
India	13.4.01
Japan	13.5.01
United States	13.6.01
Europe Overview	13.7.01
France	13.8.01
Germany	13.9.01
Italy	13.10.01
Netherlands	13.11.01
United Kingdom	13.12.01
14. Disclosure of Information to the Patent Offices	399
Australia	14.1.01
Canada	14.2.01
China	14.3.01
India	14.4.01
Japan	14.5.01
United States	14.6.01
Europe Overview	14.7.01
France	14.8.01
Germany	14.9.01
Italy	14.10.01
Netherlands	14.11.01
United Kingdom	14.12.01

D THE PERIOD OF MONOPOLY

15. Overview	411
16. The Patent Term, Renewal Fees, Withdrawals, Cease, and Lapse	413
Australia	16.1.01
Canada	16.2.01
China	16.3.01
India	16.4.01
Japan	16.5.01
United States	16.6.01
Europe Overview	16.7.01
France	16.8.01
Germany	16.9.01
Italy	16.10.01
Netherlands	16.11.01
United Kingdom	16.12.01
17. Extensions of Term and Supplementary Protection Certificates	443
Australia	17.1.01
Canada	17.2.01
China	17.3.01
India	17.4.01
Japan	17.5.01
United States	17.6.01
European Patent Office Overview	17.7.01
European Union Overview	17.8.01
France	17.9.01
Germany	17.10.01
Italy	17.11.01
Netherlands	17.12.01
United Kingdom	17.13.01

E PATENT VALIDITY

18. Overview	479
19. Patentable Subject Matter	487
Australia	19.1.01
Canada	19.2.01
China	19.3.01
India	19.4.01
Japan	19.5.01
United States	19.6.01
Europe Overview	19.7.01
France	19.8.01

Germany	19.9.01
Italy	19.10.01
Netherlands	19.11.01
United Kingdom	19.12.01
20. Priority Dates	545
Australia	20.1.01
Canada	20.2.01
China	20.3.01
India	20.4.01
Japan	20.5.01
United States	20.6.01
Europe Overview	20.7.01
France	20.8.01
Germany	20.9.01
Italy	20.10.01
Netherlands	20.11.01
United Kingdom	20.12.01
21. Novelty	573
Australia	21.1.01
Canada	21.2.01
China	21.3.01
India	21.4.01
Japan	21.5.01
United States	21.6.01
Europe Overview	21.7.01
France	21.8.01
Germany	21.9.01
Italy	21.10.01
Netherlands	21.11.01
United Kingdom	21.12.01
22. Grace Period	617
Australia	22.1.01
Canada	22.2.01
China	22.3.01
India	22.4.01
Japan	22.5.01
United States	22.6.01
Europe Overview	22.7.01
France	22.8.01
Germany	22.9.01
Italy	22.10.01
Netherlands	22.11.01
United Kingdom	22.12.01

23. Inventive Step	631
Australia	23.1.01
Canada	23.2.01
China	23.3.01
India	23.4.01
Japan	23.5.01
United States	23.6.01
Europe Overview	23.7.01
France	23.8.01
Germany	23.9.01
Italy	23.10.01
Netherlands	23.11.01
United Kingdom	23.12.01
24. Enablement/Internal Fair Basis	677
Australia	24.1.01
Canada	24.2.01
China	24.3.01
India	24.4.01
Japan	24.5.01
United States	24.6.01
Europe Overview	24.7.01
France	24.8.01
Germany	24.9.01
Italy	24.10.01
Netherlands	24.11.01
United Kingdom	24.12.01
25. Full Description/Sufficiency/Written Description	693
Australia	25.1.01
Canada	25.2.01
China	25.3.01
India	25.4.01
Japan	25.5.01
United States	25.6.01
Europe Overview	25.7.01
France	25.8.01
Germany	25.9.01
Italy	25.10.01
Netherlands	25.11.01
United Kingdom	25.12.01
26. Utility/Industrial Application	731
Australia	26.1.01
Canada	26.2.01

China	26.3.01
India	26.4.01
Japan	26.5.01
United States	26.6.01
Europe Overview	26.7.01
France	26.8.01
Germany	26.9.01
Italy	26.10.01
Netherlands	26.11.01
United Kingdom	26.12.01
 27. Indefiniteness/Clarity	 749
Australia	27.1.01
Canada	27.2.01
China	27.3.01
India	27.4.01
Japan	27.5.01
United States	27.6.01
Europe Overview	27.7.01
France	27.8.01
Germany	27.9.01
Italy	27.10.01
Netherlands	27.11.01
United Kingdom	27.12.01
 28. Secret Use before Priority Date	 765
Australia	28.1.01
Canada	28.2.01
China	28.3.01
India	28.4.01
Japan	28.5.01
United States	28.6.01
Europe Overview	28.7.01
France	28.8.01
Germany	28.9.01
Italy	28.10.01
Netherlands	28.11.01
United Kingdom	28.12.01
 29. Unity of Invention	 775
Australia	29.1.01
Canada	29.2.01
China	29.3.01
India	29.4.01
Japan	29.5.01
United States	29.6.01

Europe Overview	29.7.01
France	29.8.01
Germany	29.9.01
Italy	29.10.01
Netherlands	29.11.01
United Kingdom	29.12.01
30. Fraud and Misrepresentation/Inequitable Conduct	797
Australia	30.1.01
Canada	30.2.01
China	30.3.01
India	30.4.01
Japan	30.5.01
United States	30.6.01
Europe Overview	30.7.01
France	30.8.01
Germany	30.9.01
Italy	30.10.01
Netherlands	30.11.01
United Kingdom	30.12.01
31. Lack of Entitlement to the Invention	811
Australia	31.1.01
Canada	31.2.01
China	31.3.01
India	31.4.01
Japan	31.5.01
United States	31.6.01
Europe Overview	31.7.01
France	31.8.01
Germany	31.9.01
Italy	31.10.01
Netherlands	31.11.01
United Kingdom	31.12.01
F AMENDMENT	
32. Overview	825
33. When Patents can be Amended	827
Australia	33.1.01
Canada	33.2.01
China	33.3.01
India	33.4.01
Japan	33.5.01
United States	33.6.01
Europe Overview	33.7.01

France	33.8.01
Germany	33.9.01
Italy	33.10.01
Netherlands	33.11.01
United Kingdom	33.12.01
34. What Amendments are Allowable?	847
Australia	34.1.01
Canada	34.2.01
China	34.3.01
India	34.4.01
Japan	34.5.01
United States	34.6.01
Europe Overview	34.7.01
France	34.8.01
Germany	34.9.01
Italy	34.10.01
Netherlands	34.11.01
United Kingdom	34.12.01
35. Amended Specifications, Reissue Applications, Certificates of Correction	877
Australia	35.1.01
Canada	35.2.01
China	35.3.01
India	35.4.01
Japan	35.5.01
United States	35.6.01
Europe Overview	35.7.01
France	35.8.01
Germany	35.9.01
Italy	35.10.01
Netherlands	35.11.01
United Kingdom	35.12.01
 G INVALIDITY PROCEEDINGS AND STRATEGY 	
36. Overview	897
37. Third Party Intervention during Prosecution of an Application	901
Australia	37.1.01
Canada	37.2.01
China	37.3.01
India	37.4.01
Japan	37.5.01
United States	37.6.01
Europe Overview	37.7.01
France	37.8.01

Germany	37.9.01
Italy	37.10.01
Netherlands	37.11.01
United Kingdom	37.12.01
38. Opposition Proceedings	915
Australia	38.1.01
Canada	38.2.01
China	38.3.01
India	38.4.01
Japan	38.5.01
United States	38.6.01
Europe Overview	38.7.01
France	38.8.01
Germany	38.9.01
Italy	38.10.01
Netherlands	38.11.01
United Kingdom	38.12.01
39. Re-Examination	945
Australia	39.1.01
Canada	39.2.01
China	39.3.01
India	39.4.01
Japan	39.5.01
United States	39.6.01
Europe Overview	39.7.01
France	39.8.01
Germany	39.9.01
Italy	39.10.01
Netherlands	39.11.01
United Kingdom	39.12.01
40. Revocation/Nullification Proceedings	961
Australia	40.1.01
Canada	40.2.01
China	40.3.01
India	40.4.01
Japan	40.5.01
United States	40.6.01
Europe Overview	40.7.01
France	40.8.01
Germany	40.9.01
Italy	40.10.01
Netherlands	40.11.01
United Kingdom	40.12.01

41. Declarations of Validity	993
Australia	41.1.01
Canada	41.2.01
China	41.3.01
India	41.4.01
Japan	41.5.01
United States	41.6.01
Europe Overview	41.7.01
France	41.8.01
Germany	41.9.01
Italy	41.10.01
Netherlands	41.11.01
United Kingdom	41.12.01
 H INFRINGEMENT 	
42. Overview	1001
43. Infringing Acts and ‘Literal Infringement’	1005
Australia	43.1.01
Canada	43.2.01
China	43.3.01
India	43.4.01
Japan	43.5.01
United States	43.6.01
Europe Overview	43.7.01
France	43.8.01
Germany	43.9.01
Italy	43.10.01
Netherlands	43.11.01
United Kingdom	43.12.01
 44. Infringement by Equivalents/Non-Literal Infringement	 1029
Australia	44.1.01
Canada	44.2.01
China	44.3.01
India	44.4.01
Japan	44.5.01
United States	44.6.01
Europe Overview	44.7.01
France	44.8.01
Germany	44.9.01
Italy	44.10.01
Netherlands	44.11.01
United Kingdom	44.12.01

45. Indirect Infringement	1055
Australia	45.1.01
Canada	45.2.01
China	45.3.01
India	45.4.01
Japan	45.5.01
United States	45.6.01
Europe Overview	45.7.01
France	45.8.01
Germany	45.9.01
Italy	45.10.01
Netherlands	45.11.01
United Kingdom	45.12.01
46. Infringement Proceedings	1077
Australia	46.1.01
Canada	46.2.01
China	46.3.01
India	46.4.01
Japan	46.5.01
United States	46.6.01
Europe Overview	46.7.01
France	46.8.01
Germany	46.9.01
Italy	46.10.01
Netherlands	46.11.01
United Kingdom	46.12.01
47. Remedies for Patent Infringement	1117
Australia	47.1.01
Canada	47.2.01
China	47.3.01
India	47.4.01
Japan	47.5.01
United States	47.6.01
Europe Overview	47.7.01
France	47.8.01
Germany	47.9.01
Italy	47.10.01
Netherlands	47.11.01
United Kingdom	47.12.01
48. Restrictions on Remedies	1155
Australia	48.1.01
Canada	48.2.01

China	48.3.01
India	48.4.01
Japan	48.5.01
United States	48.6.01
Europe Overview	48.7.01
France	48.8.01
Germany	48.9.01
Italy	48.10.01
Netherlands	48.11.01
United Kingdom	48.12.01